KNE Kane Biotech Inc.

0.0210USD0.0300 CAD · TSXV0.00%Mkt Cap: 4.30M USDP/E: —

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company d…

Key Statistics

Company
Market Cap4.30M USD
Enterprise Value5.08M USD
Revenue (TTM)27.07K USD
Gross Profit-447 USD
Net Income (TTM)-1.90M USD
Revenue/Share0.00 USD
Last Price0.0210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA4838092084
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.76
EV/Revenue187.50
P/S158.88
P/B-6.00
EPS (TTM)-0.01 USD
EPS (Forward)—
52W Range
0.010543% of range0.0350
52W High0.0350 USD
52W Low0.0105 USD
Profitability
Gross Margin-0.15%
Oper. Margin-6794.22%
EBITDA Margin0.00%
Profit Margin-636.00%
ROE364.51%
ROA-99.53%
ROIC-389.07%
ROCE-1143.07%
Growth
Revenue Growth-70.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.28M USD
CapEx (TTM)79.08K USD
FCF Margin-4431.31%
FCF Yield-27.89%
Net Debt774.78K USD
Net Debt/EBITDA-0.42
Net Debt/FCF—
Balance Sheet
Debt/Equity-3.09
Current Ratio0.61
Quick Ratio0.35
Book Value/Sh-0.0035 USD
Cash/Share0.0028 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateMar 13, 2017
Splits
Last Split1:5
Split DateMar 13, 2017
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.205.06M
Float113.52M
Insiders39.82%
Institutions0.00%
Short Interest
Short Ratio0.4d
Short % Out.0.01%
Shares Short23.39K
Short (prev mo.)18.34K
Technical
SMA 500.0221 (-5.1%)
SMA 2000.0233 (-10.0%)
Beta0.25
S&P 52W Chg12.00%
Avg Vol (30d)47.94K
Avg Vol (10d)49.03K
Technical Indicators
RSI (14)47.3
MACD-0.0001
MACD Signal0.0003
MACD Hist.-0.0004
BB Upper0.0256 USD
BB Middle0.0222 USD
BB Lower0.0188 USD
BB Width30.83%
ATR (14)0.0016 USD
Vol Ratio (20d)0.18x

About Kane Biotech (CVE: KNE)

›

Kane Biotech (CVE: KNE) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.

The shares were at 0.0300 CAD on 19 November 2026, down 25.0% over 52 weeks. Its 52-week range is 0.0150 CAD to 0.0500 CAD: the price is 40.0% below the high and 100.0% above the low.

Its market capitalisation is 6.15M CAD.

Kane Biotech reports return on equity of 364.5% and revenue down 70.9% year over year.

Its debt exceeds its cash by 1.11M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 26 November 2026.